ArticleMolecular neurobiology2025
Resident Macrophages in the Cervical Sympathetic Ganglia Participate in P2Y12 Receptor Mediated Diabetic Cardiac Autonomic Neuropathy.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Diabetic cardiac autonomic neuropathy (DCAN) represents a significant and prevalent complication of diabetes. Further research is required to ascertain the role of the P2Y12 receptor, which is expressed on macrophages and satellite glial cells (SGCs), in the pathophysiology of DCAN. The objective of this study was to ascertain whether resident macrophages in the superior cervical ganglion (SCG) are involved in the pathological changes associated with DCAN, which are mediated by the P2Y12 receptor in satellite glial cells (SGCs). The findings showed that DCAN rats had higher sympathetic nerve discharge activity than the control group. Furthermore, the expression of P2Y12 receptor, glial fibrillary acidic protein (GFAP), macrophage-like targets (colony-stimulating factor 1 receptor (CSF1R), colony-stimulating factor 1 (CSF1)), and interleukin-34 (IL-34) in SCG among DCAN rats was clearly elevated. Moreover, co-expression levels of NeuN and CSF1 in neurons, P2Y12 and GFAP as well as P2Y12 and IBA-1 in SCGs were increased. However, treatment with P2Y12 shRNA led to significant reductions in all above parameters. The action mechanism may involve reducing the expression of P2Y12 receptors in macrophages and SGCs, decreasing the expression of CSF1 in SCG neurons to weaken the CSF1-CSF1R signal, inhibiting the activation of macrophages and SGCs, and reducing the release of inflammatory factors. This ultimately alleviated abnormal neuronal excitation in SCG and maintaining balance in cardiac autonomic nervous activity. Therefore, targeting the P2Y12 receptor to disrupt the resident macrophages participate in pathological changes, may be an effective approach for improving DCAN.
Indexed as
Identifiers
40146499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.